NCT04248257 is a NA clinical trial of PeACE in Breast Cancer Risk, sponsored by Georgetown University.

Who is sponsoring NCT04248257?

NCT04248257 is sponsored by Georgetown University.

What drugs are being tested in NCT04248257?

Interventions in NCT04248257: PeACE, Community peer coaching.

What condition does NCT04248257 study?

NCT04248257 studies Breast Cancer Risk.

Is NCT04248257 still recruiting?

NCT04248257 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT04248257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peer Support For Young Adult Women With High Breast Cancer Risk

Active, enrolled NA Last updated 13 April 2026

What this trial tests

NA trial testing PeACE in Breast Cancer Risk in 560 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 July 2020

Primary endpoint
30 April 2026

31 December 2026

Quick facts

Lead sponsor	Georgetown University
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	560
Start date	15 July 2020
Primary completion	30 April 2026
Estimated completion	31 December 2026
Sites	6 locations across United States

Drugs / interventions tested

PeACE
Community peer coaching

Conditions studied

Breast Cancer Risk — all drugs for Breast Cancer Risk →

Sponsor

Georgetown University

Who can join

18 and older, any sex, with Breast Cancer Risk. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will recruit young adult female relatives (YARs) of male or female carriers of BRCA1/2. YARs who consent to participate will be randomized to either a 3-session peer coach-led telephone counseling intervention or usual care navigation to peer support interventions provided by community organizations that support the hereditary cancer community. Study aims are to 1) Assess intervention effects on distress and decision making outcomes, including uptake of counseling for untested YARs, 2) Identify YARs most likely to engage with and benefit from the intervention, 3) Understand intervention mechanisms. Participants will complete interviews at baseline, 1, 6, and 12 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.
O'Neill SC, Hamilton JG, Conley CC, Peshkin BN, et al · · 2021 · cited 16× · PMID 34565430 · DOI 10.1186/s13053-021-00198-7

Verify or expand the search:

Other recruiting trials for Breast Cancer Risk

Currently open trials in the same condition.

NCT07121972 — Mirai-MRI: Validation of AI Models for Breast Cancer Risk · NA · recruiting
NCT06773897 — Rutgers University Study of the Genetics of Breast Cancer. · recruiting
NCT03987633 — EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality · recruiting
NCT06939049 — Development of New Methodologies and Innovative Tools for the diagnoSi and Therapeutic Treatment of uMAni Epithelial Tum · recruiting

Other Georgetown University trials

Trials by the same sponsor.

NCT07228000 — Bundled Cancer Screening and Genetic Services Navigation · NA · not yet recruiting
NCT07128927 — Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors · NA · recruiting
NCT06046287 — Daratumumab for Polyneuropathy Associated With MGUS · Phase 2 · withdrawn
NCT06980103 — Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyro · NA · recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04248257 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Georgetown University
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04248257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing